One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets

doi:10.19803/j.1672-8629.20240433

Abstract

Abstract: Objective To investigate the clinical characteristics, mechanism and treatment strategies of heart failure caused by furmonertinib mesilate tablets. Methods A case of heart failure caused by the third generation of epidermal growth factor receptor-tyrosine kinase inhibitor (furmonertinib) in a female patient with advanced lung cancer was summarized. The potential mechanism and treatment strategies were studied based on a literature review. Results The patient developed heart failure 3 months after administration of furmonertinib. Considering that similar medication had been reported to induce heart failure, furmonertinib was believed to have induced heart failure in this patient after other potential risks were ruled out. Her cardiac function improved after reduction of the dosage of furmonertinib and anti-heart failure therapy. Conclusion The use of furmonertinib can cause heart failure, so echocardiography should be monitored for early identification and management in clinical practice.

Key words: Furmonertinib Mesilate, Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Lung Cancer, Heart Failure, QT Interval Prolongation, Adverse Drug Reaction

CLC Number:

ZHANG Wei, XU Dongjie, JIN Yu, ZOU Ying, ZHANG Ting, ZHOU Jiancheng. One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 113-115.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240433

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I1/113

References

[1] CHEN L, ZHOU Y, GAN C, et al.Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences[J]. Cancer Invest, 2022, 40(7): 590-603.
[2] SHI Y, HU X, ZHANG S, et al.Efficacy, Safety, and Genetic Analysis of Furmonertinib (AST2818) in Patients with EGFR T790M Mutated Non-Small-Cell Lung Cancer: a Phase 2b, Multicentre, Single-Arm, Open-Label Study[J]. Lancet Respir Med, 2021, 9(8): 829-839.
[3] SHI Y, CHEN G, WANG X, et al.Furmonertinib (AST2818) vs Gefitinib as First-Line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer (FURLONG): a Multicentre, Double-Blind, Randomised Phase 3 Study[J]. Lancet Respir Med, 2022, 10(11): 1019-1028.
[4] AN T, HAN S.Cardiovascular Toxicity of Targeted Therapy in Patients with Lung Cancer[J]. Chin J Clin Oncol(中国肿瘤临床), 2021, 48(6): 311-316.
[5] ANAND K, ENSOR J, TRACHTENBERG B, et al.Osimertinib-Induced Cardiotoxicity: a Retrospective Review of the FDA Adverse Events Reporting System (FAERS)[J]. JACC CardioOncol, 2019, 1(2): 172-178.
[6] KUNIMASA K, KAMADA R, OKA T, et al.Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated with Osimertinib[J]. JACC CardioOncol, 2020, 2(1): 1-10.
[7] EWER MS, TEKUMALLA SH, WALDING A, et al.Cardiac Safety of Osimertinib: a Review of Data[J]. J Clin Oncol, 2021, 39(4): 328-337.
[8] CHEN JJ, QIAN PP, CAO K, et al.Comparison and Analysis of Causality Assessment Method in China and Naranjo's Method in the Evaluation of Adverse Drug Reactions[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(8): 988-992.
[9] CHEN S, WAN C, ZHANG YR.Research Progress of Cardiotoxicity Related to the Third Generation of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2024, 26(2): 106-110.
[10] CROSS DA, ASHTON SE, GHIORGHIU S, et al.AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer[J]. Cancer Discov, 2014, 4(9): 1046-1061.
[11] LU Z, WU CY, JIANG YP, et al. Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome[J]. Sci Transl Med, 2012, 4(131): 131ra50.
[12] LI P, TIAN X, WANG G, et al.Acute Osimertinib Exposure Induces Electrocardiac Changes by Synchronously Inhibiting the Currents of Cardiac Ion Channels[J]. Front Pharmacol, 2023, 14: 1177003.
[13] HERRMANN J, YANG EH, ILIESCU C, et al.Response by Herrmann et al to Letter Regarding Article,“Vascular Toxicities of Cancer Therapies: the Old and the New-an Evolving Avenue”[J]. Circulation, 2016, 134(20): 466-467.
[14] Guidelines Working Committee of Chinese Society of Clinical Oncology. Cardio-Onclolgy Guideline 2023
(肿瘤心脏病学指南2023)[M]肿瘤心脏病学指南2023)[M]. Beijing: People's Medical Publishing House, 2023: 78.
[15] LYON AR, LOPEZ-FERNANDEZ T, COUCH LS, et al.2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)[J]. Eur Heart J, 2022, 43(41): 4229-4361.